C. Frances
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
C. Frances has a total of 81 co-authors. Here are the top co-authors by number of shared publications:
- Damien Sene
Service de médecine interne, hôpital Lariboisière, Paris
3 shared publications - Patrice Cacoub
Sorbonne Universités, UPMC Univ Paris 06, UMR 7211, and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), F-75005, Paris, France
3 shared publications - Jean-David Bouaziz
Université Paris Cité, INSERM U1342, Institut de Recherche Saint‐Louis Paris France
2 shared publications - Marie Jachiet
Dermatology Department Saint Louis Hospital Paris France
2 shared publications - Stéphane Barete
Dermatology Department Pitié‐Salpêtrière Hospital, AP–HP, Sorbonne University Paris France
2 shared publications A. Bérezné
Internal Medicine, Cochin, Paris
1 shared publication
Latest Publications
- 1 December 2018
- Published by Elsevier in Annales de Dermatologie et de Vénéréologie
- Vol. 145 (12) , S303
Fasciite à éosinophiles : caractéristiques cliniques, histologiques, thérapeutiques et pronostiques à partir d’une série de 79 cas
- 1 December 2018
- Published by Elsevier in Annales de Dermatologie et de Vénéréologie
- Vol. 145 (12) , S303
Fasciite à éosinophiles : caractéristiques cliniques, histologiques, thérapeutiques et pronostiques à partir d’une série de 79 cas
- 1 December 2017
- Published by Elsevier in Annales de Dermatologie et de Vénéréologie
- Vol. 144 (12) , S124-S125
Caractéristiques clinicobiologiques, facteurs pronostiques et prise en charge thérapeutique du scléromyxœdème : étude rétrospective multicentrique
- 1 December 2017
- Published by Elsevier in Annales de Dermatologie et de Vénéréologie
- Vol. 144 (12) , S124-S125
Caractéristiques clinicobiologiques, facteurs pronostiques et prise en charge thérapeutique du scléromyxœdème : étude rétrospective multicentrique
- 1 September 2014
- Published by Elsevier in Journal of Medical Mycology
- Vol. 24 (3) , e120
Infections fongiques à champignons dématies chez deux patients transplantés rénaux
- 1 September 2014
- Published by Elsevier in Journal of Medical Mycology
- Vol. 24 (3) , e120
Infections fongiques à champignons dématies chez deux patients transplantés rénaux
- 1 June 2012
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 71 (Suppl 3) , 235
THU0237 Impact of recurrent ischemic digital ulcers on hand disability in systemic sclerosis –
Background Ischemic digital ulcers (DU) are a common complication of systemic sclerosis (SSc). Objectives To evaluate the impact of recurrent DU on hand disability in a prospective, longitudinal, observational study of 24 months. Methods Patients fulfilled ACR or Leroy-Medsger criteria for SSc, experienced at least one DU during the previous year with or without active DU at inclusion, and were eligible for bosentan therapy. Data were collected on SSc, characteristics of past and present DU, modified Rodnan skin score, factors influencing hand function and mobility, disability scores (Cochin hand function scale - CHFS, health assessment questionnaire disability index - HAQ-DI), and quality of life (SF36). Results 217 patients were included between October 2009 and March 2011 in 50 centers. The interim analysis includes 184 patients (128 women). Mean age was 43±15 years at diagnosis of SSc and 53±15 years at inclusion. SSc was diffuse in 44% of patients and Raynaud’s phenomenon (RP) started 14±12 years before inclusion. 11% of patients had pulmonary arterial hypertension. Mean Rodnan score was 14.3±8.8. Time elapsed since the first DU was 6±7 years. In 47% of patients, DU was an early complication (first non-RP sign) and 59% had recurrent DU. Sequelae of DU included loss of substance (62%), autoamputation (8%), and surgical amputation (10%). Complications were infection (8%), gangrene (5%), and osteitis (2%). 54% of patients had at least one active DU at inclusion. In these patients, the mean number of DU was 2.3±1.9; 54% had more than one DU, 37% had both hands involved, and on average 2.2±1.7 fingers were affected. 21% of cases had at least one extended DU (>1cm). Concomitant mechanical ulcers were localized at the dorsal face of fingers (19%), bony reliefs (13%), or calcinosis (1%). DU were painful (visual analogue scale, 6.18±2.56 vs. 2.49±2.56 without DU) and disabling, involving the dominant hand in 72% of patients. DU worsened hand disability (median CHFS, 42 with active DU vs. 26 without DU, pConclusions DU represent an early complication of SSc. They are painful, affecting often multiple fingers and both hands. In patients with SSc, DU are significantly associated with hand disability. Prospective follow-up at two years will allow to further elucidate the specific role that DU episodes play in the disability of these patients. Disclosure of Interest L. Mouthon Consultant for: Lilly, Actelion France, GSK, Pfizer, P. Carpentier Consultant for: Actelion, A. Khau Van Kien: None Declared, P. Clerson: None Declared, H. Maillard: None Declared, E. Hachulla Consultant for: Actelion, GSK, Pfizer, C. Frances: None Declared, E. Diot: None Declared, C. Lok Consultant for: Actelion, E. Puzenat Consultant for: Actelion, A. Sparsa Consultant for: Actelion, A. Bérezné: None Declared, V. Gressin Employee of: Actelion France, M.-A. Richard Consultant for: Actelion
- 1 June 2012
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 71 (Suppl 3) , 235
THU0237 Impact of recurrent ischemic digital ulcers on hand disability in systemic sclerosis –
Background Ischemic digital ulcers (DU) are a common complication of systemic sclerosis (SSc). Objectives To evaluate the impact of recurrent DU on hand disability in a prospective, longitudinal, observational study of 24 months. Methods Patients fulfilled ACR or Leroy-Medsger criteria for SSc, experienced at least one DU during the previous year with or without active DU at inclusion, and were eligible for bosentan therapy. Data were collected on SSc, characteristics of past and present DU, modified Rodnan skin score, factors influencing hand function and mobility, disability scores (Cochin hand function scale - CHFS, health assessment questionnaire disability index - HAQ-DI), and quality of life (SF36). Results 217 patients were included between October 2009 and March 2011 in 50 centers. The interim analysis includes 184 patients (128 women). Mean age was 43±15 years at diagnosis of SSc and 53±15 years at inclusion. SSc was diffuse in 44% of patients and Raynaud’s phenomenon (RP) started 14±12 years before inclusion. 11% of patients had pulmonary arterial hypertension. Mean Rodnan score was 14.3±8.8. Time elapsed since the first DU was 6±7 years. In 47% of patients, DU was an early complication (first non-RP sign) and 59% had recurrent DU. Sequelae of DU included loss of substance (62%), autoamputation (8%), and surgical amputation (10%). Complications were infection (8%), gangrene (5%), and osteitis (2%). 54% of patients had at least one active DU at inclusion. In these patients, the mean number of DU was 2.3±1.9; 54% had more than one DU, 37% had both hands involved, and on average 2.2±1.7 fingers were affected. 21% of cases had at least one extended DU (>1cm). Concomitant mechanical ulcers were localized at the dorsal face of fingers (19%), bony reliefs (13%), or calcinosis (1%). DU were painful (visual analogue scale, 6.18±2.56 vs. 2.49±2.56 without DU) and disabling, involving the dominant hand in 72% of patients. DU worsened hand disability (median CHFS, 42 with active DU vs. 26 without DU, pConclusions DU represent an early complication of SSc. They are painful, affecting often multiple fingers and both hands. In patients with SSc, DU are significantly associated with hand disability. Prospective follow-up at two years will allow to further elucidate the specific role that DU episodes play in the disability of these patients. Disclosure of Interest L. Mouthon Consultant for: Lilly, Actelion France, GSK, Pfizer, P. Carpentier Consultant for: Actelion, A. Khau Van Kien: None Declared, P. Clerson: None Declared, H. Maillard: None Declared, E. Hachulla Consultant for: Actelion, GSK, Pfizer, C. Frances: None Declared, E. Diot: None Declared, C. Lok Consultant for: Actelion, E. Puzenat Consultant for: Actelion, A. Sparsa Consultant for: Actelion, A. Bérezné: None Declared, V. Gressin Employee of: Actelion France, M.-A. Richard Consultant for: Actelion
- 1 December 2011
- Published by Elsevier in Annales de Dermatologie et de Vénéréologie
- Vol. 138 (12) , A98-A99
Fasciite à éosinophiles : caractéristiques clinico-biologiques et histologiques ; analyse de la prise en charge thérapeutique et identification de facteurs pronostiques
- 1 December 2011
- Published by Elsevier in Annales de Dermatologie et de Vénéréologie
- Vol. 138 (12) , A98-A99
Fasciite à éosinophiles : caractéristiques clinico-biologiques et histologiques ; analyse de la prise en charge thérapeutique et identification de facteurs pronostiques
- 1 June 2009
- Published by Elsevier in La Revue de Médecine Interne
- Vol. 30, S49
Histiocytose Langerhansienne : suivi en médecine interne d’une cohorte monocentrique de 26 patients
- 1 June 2009
- Published by Elsevier in La Revue de Médecine Interne
- Vol. 30, S49
Histiocytose Langerhansienne : suivi en médecine interne d’une cohorte monocentrique de 26 patients
- Open Access
- 16 December 2003
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 57 (1) , 115-116
Paediatric methylphenidate (Ritalin®) restrictive conditions of prescription in France
- 16 December 2003
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 57 (1) , 115-116
Open AccessPaediatric methylphenidate (Ritalin®) restrictive conditions of prescription in France
- 1 February 2001
- Published by Elsevier in Transplantation Proceedings
- Vol. 33 (1-2) , 1722
Immunohistologic studies of the skin of human hand allografts: our experience with two patients
- 1 February 2001
- Published by Elsevier in Transplantation Proceedings
- Vol. 33 (1-2) , 1722
Immunohistologic studies of the skin of human hand allografts: our experience with two patients